Leerink Partnrs Has Weak Outlook for Biogen FY2025 Earnings

Biogen Inc. (NASDAQ:BIIB) – Leerink Partnrs lowered their FY2025 earnings estimates for shares of Biogen in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biotechnology company will earn $16.50 per share for the year, down from their prior forecast of $17.20. The consensus estimate for Biogen’s current full-year earnings is $16.41 per share. Leerink Partnrs also issued estimates for Biogen’s FY2026 earnings at $16.65 EPS.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, beating the consensus estimate of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.43 billion. During the same period in the prior year, the firm earned $4.36 earnings per share. Biogen’s revenue was down 2.5% compared to the same quarter last year.

Other equities research analysts also recently issued research reports about the company. Truist Financial dropped their target price on Biogen from $302.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Jefferies Financial Group cut Biogen from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $250.00 to $180.00 in a report on Monday, December 9th. Wolfe Research began coverage on shares of Biogen in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Robert W. Baird lifted their price target on shares of Biogen from $294.00 to $300.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. Finally, Stifel Nicolaus lowered shares of Biogen from a “buy” rating to a “hold” rating and set a $175.00 price objective on the stock. in a report on Monday, December 16th. Sixteen investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $228.80.

Biogen Stock Down 0.7 %

NASDAQ:BIIB opened at $144.41 on Thursday. The company has a market cap of $21.04 billion, a price-to-earnings ratio of 13.05, a P/E/G ratio of 1.64 and a beta of -0.07. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. The stock’s fifty day moving average price is $151.55 and its two-hundred day moving average price is $180.05. Biogen has a 52-week low of $139.71 and a 52-week high of $251.99.

Institutional Investors Weigh In On Biogen

Several institutional investors have recently added to or reduced their stakes in the stock. Ashton Thomas Securities LLC acquired a new position in Biogen during the 3rd quarter worth approximately $33,000. Golden State Wealth Management LLC acquired a new position in shares of Biogen during the 4th quarter worth about $41,000. Venturi Wealth Management LLC raised its stake in Biogen by 73.8% in the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 93 shares during the period. Itau Unibanco Holding S.A. lifted its position in shares of Biogen by 63.8% in the third quarter. Itau Unibanco Holding S.A. now owns 231 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 90 shares during the last quarter. Finally, Quent Capital LLC boosted its stake in shares of Biogen by 31.9% during the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 72 shares during the period. 87.93% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.